Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2009 Jan 12;23(1):19–23. doi: 10.1002/jcla.20280

Anti‐C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus

Carlos Geraldo Moura 1, Isabella Lima 2, Lúcio Barbosa 3, Daniel Athanazio 3, Eliana Reis 3, Mitermayer Reis 3, Rufus W Burlingame 4, Mittermayer B Santiago 5,✉
PMCID: PMC6648991  PMID: 19140207

Abstract

Background: Anti‐C1q antibodies have been described in systemic lupus erythematosus (SLE) as well as in other connective tissue diseases. They have been considered as a marker for disease activity and presence of nephritis.

Objective: The aim of this study was to determine the prevalence of anti‐C1q antibodies in Brazilian lupus patients as well as analyze their association with different clinical and serologic parameters.

Methods: Sera from 81 SLE patients, based on the American College of Rheumatology (ACR) criteria, were collected from a lupus referral outpatient clinic in Salvador, Brazil. Antibodies to C1q were detected by an enzyme‐linked immunoassay (ELISA) kit and antibodies to other cellular antigens identified by indirect immunofluorescence on HEp‐2 cell substrate (ANA), or Crithidia luciliae (dsDNA), and to nucleosome by ELISA. A cutoff of 20 U wasestablished for anti‐C1q and antinucleosome assays.

Results: Anti‐C1q antibodies were detected in 39.5% (32/81) of SLE sera. The presence of anti‐C1q antibodies was associated with proteinuria (P=0.028) but not with other laboratory or clinical features, such as antinucleosome or anti‐dsDNA antibodies, hematuria, urinary casts or renal failure, leukopenia, pericarditis, pleuritis, malar rash, seizures, and psychosis. There was a positive correlation between the titers of anti‐C1q antibodies and the systemic lupuis erythematosus disease activity index (SLEDAI) score (r=0.370; P=0.001).

Conclusion: This study in Brazilian SLE patients confirms previous findings of the association of anti‐C1q antibodies with nephritis and disease activity. J. Clin. Lab. Anal. 23:19–23, 2009. © 2009 Wiley‐Liss, Inc.

Keywords: autoantibodies, anti‐C1q antibodies, systemic lupus erythematosus, nephritis

REFERENCES

  • 1. Kallel‐Sellami M, Baili‐Klila L, Zerzeri Y, et al. Pediatric systemic lupus erythematosus with C1q deficiency. Ann N Y Acad Sci 2007;1108:193–196. [DOI] [PubMed] [Google Scholar]
  • 2. Trendelenburg M, Lopez‐Trascasa M, Potlukova E, et al. High prevalence of anti‐C1q antibodies in biopsy‐proven active lupus nephritis. Nephrol Dial Transplant 2006;21:3115–3121. [DOI] [PubMed] [Google Scholar]
  • 3. Mosca M, Chimenti D, Pratesi F, et al. Prevalence and clinico‐serological correlations of anti‐alpha‐enolase, anti‐C1q, and anti‐dsDNA antibodies in patients with systemic lupus erythematosus. J Rheumatol 2006;33:695–697. [PubMed] [Google Scholar]
  • 4. Horak P, Hermanova Z, Zadrazil J, et al. C1q complement component and ‐antibodies reflect SLE activity and kidney involvement. Clin Rheumatol 2006;25:532–536. [DOI] [PubMed] [Google Scholar]
  • 5. Sinico RA, Radice A, Ikehata M, et al. Anti‐C1q autoantibodies in lupus nephritis: Prevalence and clinical significance. Ann N Y Acad Sci 2005;1050:193–200. [DOI] [PubMed] [Google Scholar]
  • 6. Braun A, Sis J, Max R, et al. Anti‐chromatin and anti‐C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol 2007;36:291–298. [DOI] [PubMed] [Google Scholar]
  • 7. Saadoun D, Sadallah S, Trendelenburg M, et al. Anti‐C1q antibodies in hepatitis C virus infection. Clin Exp Immunol 2006;145:308–312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Moroni G, Trendelenburg M, Del Papa N, et al. Anti‐C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001;37:490–498. [DOI] [PubMed] [Google Scholar]
  • 9. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti‐C1q antibodies in nephritis: Correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005;64:444–448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Shoenfeld Y, Szyper‐Kravitz M, Witte T, et al. Autoantibodies against protective molecules—C1q, C‐reactive protein, serum amyloid P, mannose‐binding lectin, and apolipoprotein A1: Prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:227–239. [DOI] [PubMed] [Google Scholar]
  • 11. Tsacheva I, Radanova M, Todorova N, Argirova T, Kishore U. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol Immunol 2007;44:2147–2151. [DOI] [PubMed] [Google Scholar]
  • 12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. [DOI] [PubMed] [Google Scholar]
  • 13. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–640. [DOI] [PubMed] [Google Scholar]
  • 14. Oelzner P, Deliyska B, Funfstuck R, Hein G, Herrmann D, Stein G. Anti‐C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus—Relationship with disease activity and renal involvement. Clin Rheumatol 2003;22:271–278. [DOI] [PubMed] [Google Scholar]
  • 15. Mosca M, Strigini F, Doria A, et al. Anti‐C1q antibodies in pregnant patients with systemic lupus erythematosus. Clin Exp Rheumatol 2007;25:449–452. [PubMed] [Google Scholar]
  • 16. Chen PC, Wang CR, Liu MF, Chen FF, Liang CC. Correlation between the renal C1q deposition and serum anti‐C1q antibody: A potential role of anti‐C1q antibody in lupus nephritis. Asian Pac J Allergy Immunol 2002;20:223–227. [PubMed] [Google Scholar]
  • 17. Flierman R, Daha MR. Pathogenic role of anti‐C1q autoantibodies in the development of lupus nephritis—A hypothesis. Mol Immunol 2007;44:133–138. [DOI] [PubMed] [Google Scholar]
  • 18. Trouw LA, Daha MR. Role of anti‐C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther 2005;5:243–251. [DOI] [PubMed] [Google Scholar]
  • 19. Trouw LA, Groeneveld TW, Seelen MA, et al. Anti‐C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q‐containing immune complexes. J Clin Invest 2004;114:679–688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Holers VM. Anti‐C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest 2004;114:616–619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Siegert CE, Daha MR, Swaak AJ, van der Voort EA, Breedveld FC. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1993;67:204–209. [DOI] [PubMed] [Google Scholar]
  • 22. Grootscholten C, Dieker JW, McGrath FD, et al. A prospective study of anti‐chromatin and anti‐C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis 2007;66:693–696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Lima I, Barbosa L, Lopes M, et al. Detection of antinucleosome antibodies in systemic lupus erythematosus. Rev Bras Reumatol 2007;47:160–164. [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES